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Abstract
Background
The International Study of Asthma and Allergies in Children (ISAAC) Wheezing Module is
commonly used to characterize pediatric asthma in epidemiological studies, including nearly
all airway cohorts participating in the Environmental Influences on Child Health Outcomes
(ECHO) consortium. However, there is no consensus model for operationalizing wheezing
severity with this instrument in explanatory research studies. Severity is typically measured
using coarsely-defined categorical variables, reducing power and potentially underestimating etiological associations. More precise measurement approaches could improve testing
of etiological theories of wheezing illness.

Methods
We evaluated a continuous latent variable model of pediatric wheezing severity based on
four ISAAC Wheezing Module items. Analyses included subgroups of children from three
independent cohorts whose parents reported past wheezing: infants ages 0–2 in the
INSPIRE birth cohort study (Cohort 1; n = 657), 6-7-year-old North American children from
Phase One of the ISAAC study (Cohort 2; n = 2,765), and 5-6-year-old children in the
EHAAS birth cohort study (Cohort 3; n = 102). Models were estimated using structural equation modeling.

Results
In all cohorts, covariance patterns implied by the latent variable model were consistent with
the observed data, as indicated by non-significant χ2 goodness of fit tests (no evidence of
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model misspecification). Cohort 1 analyses showed that the latent factor structure was stable across time points and child sexes. In both cohorts 1 and 3, the latent wheezing severity
variable was prospectively associated with wheeze-related clinical outcomes, including physician asthma diagnosis, acute corticosteroid use, and wheeze-related outpatient medical
visits when adjusting for confounders

Conclusion
We developed an easily applicable continuous latent variable model of pediatric wheezing
severity based on items from the well-validated ISAAC Wheezing Module. This model prospectively associates with asthma morbidity, as demonstrated in two ECHO birth cohort
studies, and provides a more statistically powerful method of testing etiologic hypotheses of
childhood wheezing illness and asthma.

Introduction
Background
Asthma is among the most common and costly diseases affecting childhood [1,2]. Large epidemiological studies aimed at advancing understanding of the development and sequelae of asthma
often rely on brief questionnaires that can be broadly implemented to characterize symptom
severity [3,4]. Investigators for the International Study of Asthma and Allergies in Children
(ISAAC) [3] developed and validated a research questionnaire assessing wheezing symptoms [3,5]
that has since been used worldwide to assess the prevalence and etiology of asthma [4,6–10]. The
ISAAC Wheezing Module (ISAAC-WM) includes eight items, four specifically focused on wheezing, either parent-reported for younger children or self-reported by older children [3]. The questionnaire and manual are available at http://isaac.auckland.ac.nz/story/methods/methods.php.
There is no consensus method for operationalizing wheezing severity using the ISAAC-WM.
Respondents endorsing past-year wheezing complete three items assessing the frequency of
wheezing episodes and negative sequelae in the past 12 months. Additionally, all respondents
report on whether or not their child experienced exercise-induced wheezing [3]. Researchers
typically stratify children into discrete severity groups based on frequency of wheezing episodes
(item 3), wheeze-related sleep disturbance (item 4), wheeze-related speech disturbance (item 5)
[7], exercise-induced wheezing (item 7), or a combination of these items [11].
Discrete severity variables are suboptimal in explanatory research as they artificially reduce
variability, grouping individuals with truly differing severity levels into the same data bins
[12]. This reduces power, likely resulting in underestimates of etiological associations and suboptimal theory testing [12,13]. A number of research groups have used exploratory techniques,
like principal components [14,15] or latent factor approaches [16,17], to develop continuous
asthma severity measures [18]. To our knowledge, however, no studies have tested the plausibility of these models using confirmatory analytic techniques. Additionally, we know of no
studies, either exploratory or confirmatory, evaluating the ability of the ISAAC-WM to capture
pediatric wheezing severity on a continuous scale for research purposes.

Purpose
There are a number of large epidemiological studies evaluating pediatric wheezing illness
using the ISAAC-WM [4,8,19,20], including nearly all airway cohorts participating in the
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Environmental Influences on Child Health Outcomes (ECHO) initiative [21]. ECHO is an
NIH-funded consortium of previously established birth cohorts aimed at understanding the
modifiable environmental etiologies of four major diseases, including asthma [21]. These studies contain rich data (e.g., early life exposures and wheeze-related clinical outcomes), providing
opportunities to test etiological models of wheezing illness development and outcomes. To
conduct strong tests of theory, however, it is critical to measure wheezing severity with optimal
precision. The purpose of this study is to demonstrate how studies using the ISAAC-WM can
use structural equation modeling (SEM) to estimate wheezing severity as a continuous latent
variable. Using a continuous latent variable approach, rather than discrete severity variables,
may lead to more precise measurement and stronger tests of etiological theory [22] in studies
using the ISAAC-WM. This, in turn, could lead to improved understanding of pediatric
wheezing illness and strengthen prevention and early intervention efforts.
SEM is a flexible multivariate statistical approach that supports precise specification of
theoretical models and estimation of latent variables representing constructs that we cannot
measure directly [22–25]. Latent factors capture shared variance among multiple measured
variables (factor indicators) believed to have a common underlying cause [25,26]. In this study,
we conceptualize wheezing illness as a latent (unobserved) variable that has measurable consequences (e.g., wheezing attacks, disturbed sleep). The four wheezing-focused ISAAC-WM
items capture and quantify these observable manifestations of wheezing illness. If we assume
that wheezing illness (the latent construct) is driving observed correlations among the ISAACWM wheezing items, then their shared variance can be used to estimate wheezing illness as a
continuous latent variable. Modeling associations with well-specified latent variables generally
results in increased statistical power [22,27].
We evaluated our proposed model of wheezing illness severity in three independent
cohorts. Two of these cohorts are part of the Children’s Respiratory Research and Environment Workgroup (CREW) within the ECHO initiative [21], and the third is a publicly available data set from the ISAAC Phase I study [6]. Nearly all ECHO airway cohorts have used the
ISAAC-WM, thus a more powerful approach to estimating severity in explanatory research
studies with this instrument may be of broad interest. We address whether the proposed latent
factor model of pediatric wheezing severity is:
1. consistent with observed data in all three cohorts
2. positively and concurrently associated with established markers of wheezing illness (convergent validity)
3. stable over repeated time points (longitudinal invariance) and across child sexes
4. positively and prospectively associated with wheeze-related clinical outcomes (predictive
validity)
A valid latent variable approach to measuring wheezing severity with the ISAAC-WM may
facilitate stronger tests of etiological theory and advancements in our understanding of pediatric wheezing illness.

Materials and methods
Data sources and measures
Table 1 provides demographic characteristics for each cohort.
Cohort 1. INSPIRE birth cohort study. The Infant Susceptibility to Pulmonary Infections and Asthma following RSV Exposure (INSPIRE) study is an ongoing population-based
birth cohort that is part of the ECHO/CREW consortium, evaluating the role of early life
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Table 1. Participant characteristics for all cohorts.
n

Proportion

Maternal History of Asthma

154

0.23

Child RSV+ Molecular Diagnostic Test

66

0.10

Maternal Prenatal Cigarette Smoking (Any)

139

0.21

Medicaid Insurance at Enrollment

377

0.57

Child Cesarean Birth Delivery

224

0.34

Child Sex: Female

250

0.38

Mother Married at Enrollment

368

0.56

African American

167

0.25

Asian

10

0.02

Native American/Native Alaskan

6

0.01

Native Hawaiian/Pacific Islander

2

0.003

White

510

0.78

Other Race

37

0.06

58

0.09

1,193

0.43

34

0.33

African American

10

0.10

Asian

7

0.07

Hispanic/Latino

4

0.04

White

80

0.78

Other Race

1

0.01

Cohort 1: INSPIRE (n = 657)

Child Race

Child Ethnicity: Hispanic/Latino
Cohort 2: ISAAC Phase 1 (n = 2,765)
Child Sex: Female
Cohort 3: EHAAS (n = 102)
Child Sex: Female
Child Race/Ethnicity

https://doi.org/10.1371/journal.pone.0194739.t001

respiratory infection in pediatric asthma [19,28]. The study enrolled term and otherwise
healthy infants (N = 1,951) in Middle Tennessee. The Vanderbilt University Institutional
Review Board (IRB) approved all study procedures. Wheezing symptoms are assessed annually
using the parent-reported ISAAC-WM [19]. Although all participants complete the ISAACWM, given our focus on wheezing severity, we included only children whose parents reported
wheezing in the first two years of life (n = 657).
At both the one- and two-year assessments, parents reported whether or not their children
used asthma medications and/or had been hospitalized for respiratory illnesses in the prior
year. With regard to asthma medications, parents were asked explicitly if their children had
been treated with any of the following: Budesonide, Fluticasone, Beclomethasone, Montelukast, Albuterol, Budesonide-Salmeterol, Fluticasone-Salmeterol, Prednisone/Prednisolone,
Dexamethasone, or any other asthma medications. At the year-three assessment, parents
reported several wheeze-related clinical outcomes: physician diagnosis of asthma at any point
in life (Absent or Present), past-year treatment of asthma symptoms with any form of corticosteroid (Never, 1–3 times, 4+ times), and past-year frequency of wheeze-related healthcare visits
(None, 1–3, 4+). When asking parents about corticosteroid use, no distinction was made
between parenteral steroids or oral corticosteroids in the questioning.
Cohort 2. ISAAC Phase 1 study. Cohort 2 analyses used publicly available data from the
ISAAC Study Phase I (http://isaac.auckland.ac.nz/phases/phaseone/results/resultsIndv.php) to
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evaluate whether the covariance patterns implied by the latent wheezing severity model established in Cohort 1 were consistent with observed covariance patterns in an independent dataset.
Detailed study procedures are available in prior publications [3,5]. ISAAC Phase I included two
cohorts of children (ages 6–7 and ages 13–14) from 38 countries. We limited analyses to 6-7-yearold children from the three North American countries: Canada, U.S.A., and Barbados. This was
felt to be most representative of the ECHO/CREW consortium sites. Analyses included the subset
of children who, by parent report, had ever had wheezing episodes (n = 2,765).
Cohort 3. EHAAS birth cohort. Cohort 3 analyses evaluated whether the latent wheezing
severity model established with Cohort 1 was consistent with observed data patterns in the
Epidemiology of Home Allergens and Asthma Study (EHAAS) study, and whether the latent
factor was prospectively associated with wheezing morbidity. EHAAS is a prospective birth
cohort study that is also part of the ECHO/CREW consortium (N = 505) [20,29–31]. Families
from a Boston hospital were eligible if the biological mother was 18+ years old at enrollment,
at least one biological parent had a history of allergies or asthma, infants were born term without major congenital anomalies and were not admitted to the neonatal intensive care unit.
Study procedures were approved by the Brigham and Women’s Hospital IRB. We evaluated
ISAAC-WM data collected when children were 5 and 6 years old. Analyses were limited to the
subsample of children whose parents reported wheezing episodes at some point during the
two-year follow-up window (n = 102). Clinical outcomes at age 7 included whether or not the
child had: (1) a physician diagnosis of asthma, (2) any prior-year wheezing-related medical visits, and (3) any prior-year wheezing-related urgent visits to a healthcare provider’s office or
emergency department.

Statistical analyses
Structural equation modeling (SEM) was the primary analytic strategy with parameters estimated via robust weighted least squares [32]. Fig 1A shows the hypothesized latent wheezing
severity model. Associations between the latent wheezing severity variable and the ordinal
ISAAC-WM severity items were estimated using a latent response variable framework
[22,32,33], in which ordered categorical outcomes (y1, y2, y3, y4) are conceptualized as coarse
approximations of underlying continuous variables (y1 , y2 , y3 , y4 ). The models used probit
regressions to estimate c-1 thresholds (τ) for ordinal outcomes, where c is the number of
ordered levels, dividing the underlying continuous distributions into discrete categories [32].
Analyses were conducted using the lavaan package version 0.5–22 [34] in R [35] and Mplus
version 7.4 [36]. Missing data in the response variables were presumed to be missing at random conditional on the model covariates [37].
The ISAAC Phase 1 data (Cohort 2) had a complex structure with children nested within
schools (j = 282) within study sites (k = 3). We used multilevel SEM [38,39] to evaluate the
latent wheezing severity factor model while accounting for clustering (dependence) within
schools (Fig 1B). On the within-school level, the wheezing severity model was identical to the
model specified in Cohort 1. On the between-schools level, we specified a saturated model
where all indicator variances and covariances were freely estimated and the indicators were
regressed on dummy variables coding study site. This approach accounts for between-school
and between-site variability, but presumes that wheezing severity is a meaningful construct
only on the within-schools level of analysis; that is, wheezing severity is only intended to be
measured as a child-level characteristic, not a school-level characteristic [40].
In the Cohort 3 analyses, to avoid sparse cells for the ISAAC-WM indicators, data for each
of the ISAAC-WM items were aggregated across the age-5 and age-6 assessments (Table 2).
These aggregated items were used in all models.
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Fig 1. Latent variable model of wheezing illness severity. Panel a shows the latent wheezing severity model used in
cohorts 1 and 3. The severity of wheezing illness is estimated as a unidimensional latent variable (η1) with four
reflective ordinal indicators: wheezing episode frequency (y1), frequency of wheeze-related sleep disturbance (y2),
wheeze-related speech disturbance (y3), and exercise-induced wheeze (y4). The ordinal indicators are presumed to be
coarse measurements of underlying continuous variables (y1 -y4 ). Panel b shows the multilevel wheezing severity
model used in the Cohort 2 analyses. The within-schools level of the model is identical to panel a. The between-schools
level of the model accounts for non-independence due to clustering within schools and study sites. Estimated
parameters are depicted in red.
https://doi.org/10.1371/journal.pone.0194739.g001

Assessing model adequacy. In all three cohorts, the degree of discrepancy between proposed models and observed data was assessed using a mean- and variance-adjusted χ2 Goodness of Fit (χ2GOF) test [32,37,41,42]. Significant χ2GOF values lead to a rejection of the null
hypothesis of a perfect correspondence between the model and the observed data [22]. We
reported two additional indices of model adequacy: the root mean error of approximation
(RMSEA) [43,44] and comparative fit index (CFI) [45]. The RMSEA provides an estimate of
the amount of misspecification per model degree of freedom with a 90% confidence interval
(CI), whereas the CFI compares the hypothesized model to a simpler baseline (null) model,
penalizing the hypothesized model for each estimated parameter [46]. Although there are no
perfect cutoff values for these indices [47], RMSEA values < .05 and CFI values  .95 are generally considered to be indicative of a desirable model [48].
It is noteworthy that, owing to the relatively small sample size, Study 3 models were underpowered to detect significant model misspecification with the χ2GOF test. Consequently, we
relied on data from studies 1 and 2 to assess whether our proposed latent wheezing severity
model was consistent with the observed data, whereas Study 3 analyses were focused on evaluating whether the latent wheezing severity variable was prospectively associated with established markers of wheezing illness severity (predictive validity).
Convergent validity. Using Cohort 1 data at both the year-one and year-two assessments,
we specified models evaluating concurrent associations between the latent wheezing severity
factor and parent-reported markers of wheezing illness: wheezing medication use (Any vs.
None) and respiratory hospitalizations (Any vs. None). These associations were adjusted for
seven potential confounders representing characteristics that have been linked to asthma risk
in prior studies [49]: maternal asthma history [50] (Absent vs. Present), maternal prenatal cigarette use [51] (None vs. Any), maternal marital status [52] (Married vs. Single), insurance at
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Table 2. Cohort 3 EHAAS study: Derived wheezing severity items characterizing the severity of wheeze across the
60- and 72-month assessments combined.
ISAAC-WM WHEEZING ITEM

DERIVED SEVERITY LEVELS COMBINING ACROSS
THE 60- AND 72-MONTH ASSESSSMENTS

Item 3. Number of wheezing attacks in past 12 months

Very infrequent (value = 0)
• None (60-Month) and 1–3 attacks (72-Month)
• 1–3 attacks (60-Month) and None (72-Month)
Infrequent (value = 1)
• 1–3 attacks (60-Month) and 1–3 attacks (72-Month)
• None (60-Month) and 4–12 attacks (72-Month)
• 4–12 attacks (60-Month) and None (72-Month)
Frequent (value = 2)
• 1–3 attacks (60-Month) and 4–12 attacks (72-Month)
• 4–12 attacks (60-Month) and 1–3 attacks (72-Month)
• None (60-Month) and 13+ attacks (72-Month)
• 13+ attacks (60-Month) and None (72-Month)
Very frequent (value = 3)
• 4–12 attacks (60-Month) and 4–12 attacks
(72-Month)
• 4–12 attacks (60-Month) and 13+ attacks (72-Month)
• 13+ attacks (60-Month) and 4–12 attacks (72-Month)
• 13+ attacks (60-Month) and 13+ attacks (72-Month)

Item 4. Child’s sleep disturbed due to wheezing

Never (value = 0)
• Never (60-Month) and Never (72-Month)
Infrequent (value = 1)
• Never (60-Month) and < 1 night/week (72-Month)
• < 1 night/week (60-Month) and Never (72-Month)
Frequent (value = 2)
• Never (60-Month) and 1+ nights/week (72-Month)
• 1+ nights/week (60-Month) and Never (72-Month)
• <1 night/week (60-Month) and <1 night/week
(72-Month)
• <1 night/week (60-Month) and 1+ nights/week
(72-Month)
• 1+ nights/week (60-Month) and <1 night/week
(72-Month)
• 1+ nights/week (60-Month) and 1+ nights/week
(72-Month)

Item 5. Wheezing ever severe enough to child’s speech
to only one or two words at a time between breaths

Absent at both assessments (value = 0)
Present at either or both assessments (value = 1)

Item 7. Wheezing or whistling in chest during or after
exercise

Absent at both assessments (value = 0)
Present at either or both assessments (value = 1)

https://doi.org/10.1371/journal.pone.0194739.t002

enrollment as a proxy for socioeconomic status [53] (Private vs. Medicaid), birth method [54]
(Vaginal vs. Cesarean), child sex [55], and child race [55] (African American, all other race
groups, and white race [reference group]). Both the markers of wheezing illness severity (validity outcomes) and the latent wheezing factor were regressed on these seven asthma risk
factors.
Latent factor stability. Using Cohort 1 data, we evaluated whether our latent wheezing
severity model was stable across the one- and two-year follow-ups using procedures described
in Liu et al. (2016) [56]. An unstable factor structure indicates that the latent construct cannot
be measured reliably in the same way across repeated assessments, making it challenging to
interpret change over time [56–58]. Four competing models, representing differing degrees of
instability, were specified and compared using scaled χ2 likelihood ratio tests [59]. Significant
χ2 tests are not desirable in this context because they indicate that models allowing for instability in the factor structure fit better than more restrictive models that assume stability. The
most desirable model allows mean levels of wheezing severity (the latent factor) to change over
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time, but holds the measurement of wheezing severity (factor loadings, thresholds, and residual variances) constant over time. In all models, the latent wheezing factor was regressed on
the seven asthma risk factors described above, with associations between risk factors and the
latent factor permitted to vary freely across time points. We used similar procedures [60] to
test whether the latent factor measurement was consistent across sexes (female vs. male children) [61].
Predictive validity. Using Cohort 1 data, we specified longitudinal models evaluating
whether the latent wheezing illness factor at the two-year assessment was prospectively associated with year-three clinical outcomes, including physician asthma diagnosis, acute corticosteroid use, and wheeze-related outpatient visits. These prospective associations were adjusted for
all seven asthma risk factors described above. Using Cohort 3 data, we evaluated whether the
latent wheezing severity variable measured at ages 5–6 was prospectively associated with
wheeze-related outcomes at age 7, adjusting for child sex and race.
Comparison to discrete severity models. Using data from Cohort 1, we gauged whether
the latent factor approach to estimating wheezing severity as a continuous construct had
greater predictive utility relative to a more traditional approach with a discrete severity variable. To accomplish this, we first derived a five-level ordinal wheezing severity variable indicating the number of ISAAC-WM wheezing items endorsed (i.e., present to some degree) at the
year-two assessment (None, 1, 2, 3, 4). We then reran the latent variable predictive validity
models described in the prior section, using the same covariates and estimation procedures,
but replacing the latent wheezing severity factor with the ordinal severity variable. This allowed
us to evaluate whether the latent variable modeling approach yielded stronger associations
with the future clinical outcomes (physician asthma diagnosis, acute corticosteroid use, and
wheeze-related outpatient visits) compared to the more traditional discrete severity approach.

Results
Table 3 provides descriptive statistics for the ISAAC-WM severity items for all three cohorts.
Separate online appendixes for Cohort 1 (S1 Appendix), Cohort 2 (S2 Appendix), and Cohort
3 (S3 Appendix) are available providing model code. For cohorts 1 and 3, we provide sufficient
summary statistics (covariance matrixes, weighted least squares weight vector, asymptotic variance matrix, and sample size) to allow others to reproduce our models (S1 File).

Model fit
Table 4 provides information about model adequacy for all models. Model numbers are provided in the table and are referenced in the text below.
Cohort 1. INSPIRE birth cohort. The unidimensional latent factor model of wheezing illness severity (Fig 1A) provided a close fit to the observed data at both the one- and two-year
assessments, as indicated by non-significant χ2GOF tests (Table 4, models 1.1 and 1.2). At both
assessments, there were strong positive associations between the latent wheezing factor and
the ISAAC-WM wheezing indicators (S1 Fig). Consistent with prior research using a different
instrument [16], information curves showed that levels of wheezing illness severity factor
could be estimated with greatest precision at moderate to high levels of illness severity: The
latent factor was less informative for children with mild wheezing symptoms (S2 Fig).
Cohort 2. ISAAC Phase 1. Consistent with Cohort 1 findings, the multilevel SEM model
evaluating the wheezing severity as a unidimensional construct yielded a non-significant
χ2GOF test (Table 4, Model 2.1), indicating a close fit to the data. Associations between the
latent factor and all four indicators were positive and significant on the within-school level of
analysis.
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Table 3. Descriptive statistics for ISAAC-wheezing module severity items.
LEVELS

COUNT

Cohort 1: INSPIRE
# of Wheeze Episodes

PROP

COUNT

1st Year of Life

PROP

2nd Year of Life

Never

205

0.31

156

0.24

1 to 3

328

0.50

274

0.42

4 to 12

73

0.11

76

0.12

13+

28

0.04

17

0.03

Missing

23

0.04

134

0.20

Never

455

0.69

336

0.51

< 1 night/week

83

0.13

93

0.14

1+ nights/week

96

0.15

94

0.14

Missing

23

0.04

134

0.20

Wheeze Disturbs Speech

Present

116

0.18

100

0.15

Missing

24

0.04

135

0.21

Exercise-Induced Wheeze

Present

67

0.10

76

0.12

Missing

14

0.02

33

0.05

Never

1,173

0.42

1 to 3

1,074

0.39

4 to 12

330

0.12

13+

107

0.04

Wheeze Disturbs Sleep

Cohort 2: ISAAC Phase 1
# of Wheeze Episodes

Missing
Wheeze Disturbs Sleep

Wheeze Disturbs Speech
Exercise-Induced Wheeze

81

0.03

1,793

0.65

< 1 night/week

641

0.23

1+ nights/week

228

0.08

Missing

103

0.04

Present

259

0.09

Missing

91

0.03

Present

714

0.26

Missing

119

0.04

Very Infrequent

31

0.30

Infrequent

39

0.38

Frequent

12

0.12

Very frequent

16

0.16

Missing

4

0.04

Never

55

0.54

Infrequent

23

0.23

Frequent

21

0.21

Missing

3

0.03

Present

11

0.11

Missing

3

0.03

Present

28

0.27

Missing

1

0.01

Never

Cohort 3: EHAAS
# of Wheeze Episodes

Wheeze Disturbs Sleep

Wheeze Disturbs Speech
Exercise-Induced Wheeze

PROP = proportion of the total sample.
https://doi.org/10.1371/journal.pone.0194739.t003

Cohort 3. EHAAS birth cohort. Consistent with findings from cohorts 1 and 2, the hypothesized unidimensional factor model yielded a non-significant w2GOF test (Table 4, Model 3.1). Thus,
there was no evidence of model misspecification. This finding should be interpreted cautiously,

PLOS ONE | https://doi.org/10.1371/journal.pone.0194739 April 17, 2018

9 / 22

A latent variable model of pediatric wheezing severity

Table 4. Indices of model adequacy.
χ2GOF

RMSEA

CFI

Model Description

Cohort 1: INSPIRE Birth Cohort
Model 1.1

Est

df

p

Est

90% CI

Est

2.35

2

.31

.02

.00, .08

1.0

Y1: Wheeze severity model

Model 1.2

3.76

2

.15

.04

.00, .10

1.0

Y2: Wheeze severity model

Model 1.3

27.19

29

.56

.00

.00, .03

1.0

Y1: Concurrent association with respiratory hospital visit
Y2: Concurrent association with respiratory hospital visit

Model 1.4

31.08

29

.36

.01

.00, .03

.97

Model 1.5

26.75

29

.59

.00

.00, .03

1.0

Y1: Concurrent association with asthma medication

Model 1.6

29.47

29

.44

.01

.00, .03

1.0

Y2: Concurrent association with asthma medication

Model 1.7

29.48

29

.44

.01

.00, .03

.99

Prospective associations with Y3 asthma diagnosis

Model 1.8

29.28

29

.45

.00

.00, .03

1.0

Prospective associations with Y3 corticosteroids

Model 1.9

29.01

29

.46

.00

.00, .03

1.0

Prospective associations with Y3 wheeze medical visits

Model 2.1

0.48

2

.79

.02

NA

1.0

Wheeze severity model

Model 2.2

7.20

5

.21

.00

NA

1.0

Regression of wheeze severity factor on child sex

Model 3.1

0.83

2

.66

.00

.00, .15

1.0

Wheeze severity model

Model 3.2

4.00

8

.86

.00

.00, .06

1.0

Regression of wheeze severity on child sex and race

Cohort 2: ISAAC Phase 1

Cohort 3: EHAAS Birth Cohort

Model 3.3

7.01

11

.80

.00

.00, .07

1.0

Predictive validity: 84-month asthma dx.

Model 3.4

7.22

11

.78

.00

.00, .07

1.0

Predictive validity: 84-month wheeze visits

Model 3.5

6.05

11

.87

.00

.00, .05

1.0

Predictive validity: 84-month ER visits

w2GOF = model chi-square goodness of fit test; RMSEA = root mean error of approximation; CFI = Comparative Fit Index; Y1-Y3 = Year 1 –Year 3; NA = RMSEA
confidence intervals were not available for multilevel SEM models.
https://doi.org/10.1371/journal.pone.0194739.t004

however, as the model was underpowered to detect a significant discrepancy between the model
and data because of the relatively small sample size in the Cohort 3 analyses.

Convergent validity
Using Cohort 1 data at both the one- and two-year assessments, the wheezing illness factor
was positively associated with hospitalization for respiratory illness (Table 5, models 1.3 and
Table 5. Cohort 1: Associations between the latent wheezing illness severity factors at both year-1 and year-2 and established markers of wheezing illness severity.
LATENT FACTOR
Marker of Wheezing Illness Severity

MODEL

EST

#

βa

95% CI
Lower

Upper

Year 1 Wheezing Illness Severity (Ages 0–1)
Ages 0–1 Wheeze -Related Hospitalizations

1.3

0.68

0.51

0.86

Ages 0–1 Asthma Medication Use

1.5

0.87

0.72

1.01

Year 2 Wheezing Illness Severity (Ages 1–2)
Ages 1–2 Wheeze -Related Hospitalizations

1.4

0.54

0.35

0.72

Ages 1–2 Asthma Medication Use

1.6

0.90

0.77

1.03

Ages 2–3 Asthma Diagnosis

1.7

0.71

0.53

0.88

Ages 2–3 Acute Corticosteroid Use

1.8

0.63

0.49

0.76

Ages 2–3 Wheeze-Related Medical Visits

1.9

0.64

0.48

0.79

a

Linear regression coefficient estimating the association between the latent wheezing illness severity factor and the continuous latent variable (y ) underlying the
observed categorical outcome variable (y) that is an established marker of wheezing severity.

https://doi.org/10.1371/journal.pone.0194739.t005
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Fig 2. Cohort 1: Concurrent associations between the latent wheezing severity factor and markers of wheezing illness in year-one. This
figure shows estimated probabilities of having at least one respiratory hospitalization (panel a; model 1.3) and using asthma medication (panel b;
model 1.5) against levels of the latent wheezing severity variable in the first year of life. As wheezing severity increases so does the estimated
probability of respiratory hospitalization and medication use. These models held all covariates constant at their median values. Dotted lines
represent 95% confidence intervals for estimated probability estimates.
https://doi.org/10.1371/journal.pone.0194739.g002

1.4) and asthma medication use (Table 5, models 1.5 and 1.6) adjusting for covariates. Fig 2
shows the magnitude of these concurrent associations at year-one.

Latent factor stability
Using Cohort 1 data, there was no evidence from likelihood ratio χ2 tests (p values  .20) that
imposing invariance restrictions on the loadings, thresholds, or unique variances across time
points worsened model fit (Table 6). Thus, there was no evidence of temporal instability,
allowing for meaningful evaluation of change in the latent factor. Additionally, there was no
evidence of latent factor instability across child sex at either year-one or year-two (p values 
.25; Table 6), indicating that the same latent wheezing severity model was reasonable for girls
and boys
Consistent with prior research [62], male children scored higher on average than female
children on the wheezing illness severity factor in all three cohorts. In Cohort 1 analyses, male
children scored 0.20 (95% CI [0.02, 0.45]) standard deviations (SDs) higher (more severe
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Table 6. Cohort 1: Comparison of models testing stability in the latent wheezing severity factor across time and across child sex.
χ2GOF

Measurement Parameters
Factor Loadings

Indicator
Thresholds

Residual Variances

Model Comparison

Est.

df

p

Models

χ2DIFF

p

Models Evaluating Measurement Stability Across One- and Two-Year Assessments
1

Free

Free

Free

61.97

62

.48

-

-

-

2

Constant

Free

Free

64.52

65

.49

2 vs 1

0.22

.97

3

Constant

Constant

Free

68.19

68

.47

3 vs 2

4.10

.20

4

Constant

Constant

Constant

69.58

72

.56

4 vs 3

0.92

.88

46.31

46

.46

-

-

-

Models Evaluating Measurement Stability Across Child Sex (Female vs. Male) at Year-One
5

Free

Free

Free

6

Constant

Free

Free

49.64

49

.45

6 vs 5

2.97

.25

7

Constant

Constant

Free

51.45

51

.46

7 vs 6

0.63

.60

8

Constant

Constant

Constant

52.69

55

.56

8 vs 7

0.68

.85

Models Evaluating Measurement Stability Across Child Sex (Female vs. Male) at Year-Two
9

Free

Free

Free

38.95

46

.76

-

-

-

10

Constant

Free

Free

41.01

49

.78

10 vs 9

0.72

.72

11

Constant

Constant

Free

42.95

51

.78

11 vs 10

1.24

.37

12

Constant

Constant

Constant

47.83

55

.74

12 vs 11

2.70

.37

w2GOF = chi-square goodness of fit statistic evaluating whether the model is consistent with the observed data; w2DIFF = chi-square test comparing the fit of competing
nested models; Free = parameter was allowed to vary freely across groups (i.e., time points or child sex); Constant = parameter was constrained to be equal across groups
(i.e., time points or child sex).
https://doi.org/10.1371/journal.pone.0194739.t006

symptoms) than females on the latent factor in the second year of life. Similarly, in cohorts 2
(model 2.2) and 3 (model 3.2), male children scored 0.09 SDs (95% CI [0.003, 0.18]) and 0.68
SDs (95% CI [0.01, 1.35]) higher on wheezing severity than females, respectively.

Predictive validity
In Cohort 1 longitudinal models, the severity of wheezing illness in the second year of life was
uniquely and prospectively associated with year-three physician asthma diagnosis (model 1.7),
acute corticosteroid use (model 1.8), and wheeze-related outpatient visits (model 1.9), adjusting for covariates (Table 5). Using Cohort 3 data, adjusting for covariates, the latent wheezing
illness factor representing wheezing severity measured at ages 5–6 was prospectively associated
with all clinical outcomes measured at age 7 (Fig 3): physician asthma diagnosis (model 3.3; β
= 0.52, 95% CI [0.22, 0.82]), wheeze -related medical visits (model 3.4; β = 0.58, 95% CI [0.20,
0.96]), and urgent wheeze-related medical visits (model 3.5; β = 0.82, 95% CI [0.41, 1.24]).

Comparison with discrete wheezing severity model
Using Cohort 1 data, the discrete wheezing severity variable coding the number of
ISAAC-WM severity items endorsed at the year-two assessment was significantly and positively associated with year-three asthma diagnosis, acute corticosteroid use, and wheeze/
asthma-related outpatient visits. Thus, the discrete severity exposure variable had utility in predicting future wheezing morbidity. However, Fig 4 illustrates the potential benefits of modeling wheezing severity as a latent continuous variable in explanatory models. Fig 4A plots the
estimated probability of a child having at least one wheeze-related medical visit in the third
year of life against the year-2 discrete wheezing severity variable, adjusting for covariates. As
the number of ISAAC-WM severity items endorsed increased in the second year of life (x-
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Fig 3. Cohort 3: Prospective associations between wheezing illness severity and wheeze-related morbidity outcomes. In the EHAAS birth
cohort study, there were strong prospective associations between the latent wheezing illness severity factor representing wheezing illness severity
from 60–72 months and three asthma morbidity outcomes at the 84-month follow-up: physician diagnosis of asthma (panel a; model 3.3), any
asthma medical visits (panel b; model 3.4), and urgent asthma/wheeze-related medical visits to either a doctor’s office or the emergency department
(panel c; model 3.5). These models held all covariates constant at their median values. Dotted lines represent 95% confidence intervals. Pseudo-R2
values represent the approximate proportion of variance in the outcome accounted for by the predictors.
https://doi.org/10.1371/journal.pone.0194739.g003

axis) the estimated probability of a child having a wheeze-related medical visit in the third year
of life (y-axis) increased. In the discrete severity model, however, there are only five possible
values of the estimated probability of year-three wheeze-related medical visits, ranging from
0.05 to 0.63, corresponding to the five levels of the discrete severity variable.
In contrast, Fig 4B shows the estimated probabilities of year-3 wheeze-related medical visits
as a function of the latent wheezing severity factor, with estimated probabilities following a
smooth curve ranging from 0.01 (at -3 SDs) to 0.82 (at +3 SDs). Going from the lowest level of
the discrete wheezing severity variable to the highest results in a 0.59 (95% CI [0.34, 0.83])
increase in the estimated probability of year-3 wheeze-related medical visits; whereas going
from 3 SDs below the mean to 3 SDs above the mean on the latent severity variable results in
an increase in the estimated probability of 0.81, 95% CI [0.67, 0.94]. Similar patterns were
observed for year-3 physician asthma diagnosis (Fig 5) and acute corticosteroid treatment (Fig
6). Also, the degree of uncertainty around the estimated probabilities was smaller when using
the latent wheezing severity model. This is consistent with our central premise that a latent
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Fig 4. Cohort 1: Estimated probability of year-three wheeze-related medical visits as a function of wheezing severity in year-2. These plots
show the strength of associations between year-2 wheezing severity (x-axis) and year-3 wheeze-related medical visits (y-axis), with all covariates
held constant at their median values. Panels a shows estimated probabilities of corticosteroid treatment being present in the third year of life as a
function of the discrete severity exposure variable; whereas panel b shows estimated probabilities vs. the latent continuous severity factor. In both
models, as year-2 wheezing severity increases, so does the estimated probability of acute corticosteroid treatment, though the range of estimated
probabilities is larger in the latent severity model. Values and 95% confidence intervals above the blue brackets show the increase in the estimated
probabilities for a given increase in wheezing severity. Dotted lines represent 95% confidence intervals for estimated probability estimates.
https://doi.org/10.1371/journal.pone.0194739.g004

severity model can provide improved estimation of severity, resulting in stronger associations
with clinical outcomes.

Discussion
Summary of key findings
The findings from three independent studies support the utility of a unidimensional latent variable approach to measuring pediatric wheezing illness severity based on items from the
ISAAC-WM in explanatory research studies. We found:
1. a close correspondence between the latent wheezing severity model and the observed data
(cohorts 1 and 2);
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Fig 5. Cohort 1: Year-3 physician asthma diagnosis as a function of wheezing severity in year-2. These plots show the strength of associations
between year-2 wheezing severity (x-axis) and year-3 physician asthma diagnosis (y-axis), with all covariates held constant at their median values.
Panels a shows estimated probabilities of a physician asthma diagnosis being present in the third year of life as a function of the discrete severity
exposure variable; whereas panel b shows estimated probabilities vs. the latent continuous severity factor. In both models, as year-2 wheezing
severity increases, so does the estimated probability of a physician asthma diagnosis being present, though the range of estimated probabilities is
larger in the latent severity model. Values and 95% confidence intervals above the blue brackets show the expected increase in the estimated
probabilities for a given increase in wheezing severity. Dotted lines represent 95% confidence intervals for estimated probability estimates.
https://doi.org/10.1371/journal.pone.0194739.g005

2. concurrent (Cohort 1) and prospective (cohorts 1 and 3) associations with wheeze-related
clinical outcomes;
3. stability in the latent wheezing severity factor structure across time points and child sex
(Cohort 1);
4. stronger prospective associations with wheezing outcomes compared to a discrete severity
variable (Cohort 1).

Interpretation and implications
Wheezing is the hallmark of asthma and an indicator of asthma control [63,64]. The ISAAC
questionnaire is a validated instrument used in epidemiologic studies worldwide [3,4]. The use
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Fig 6. Cohort 1: Year-3 estimated probability of acute corticosteroid treatment as a function of wheezing severity in year-2. These plots
show the strength of associations between year-2 wheezing severity (x-axis) and year-3 acute corticosteroid treatment (y-axis), with all covariates
held constant at their median values. Panels a shows estimated probabilities of corticosteroid treatment being present in the third year of life as a
function of the discrete severity exposure variable; whereas panel b shows estimated probabilities vs. the latent continuous severity factor. In both
models, as year-2 wheezing severity increases, so does the estimated probability of acute corticosteroid treatment, though the range of estimated
probabilities is larger in the latent severity model. Values and 95% confidence intervals above the blue brackets show the increase in the estimated
probabilities for a given increase in wheezing severity. Dotted lines represent 95% confidence intervals for estimated probability estimates.
https://doi.org/10.1371/journal.pone.0194739.g006

of wheezing questions to assess disease severity in etiological research is highly desirable, particularly for the new ECHO consortium in which nearly all of the asthma birth cohorts utilized
the ISAAC-WM. Our latent variable approach yields a continuous measure of wheezing illness
severity that capitalizes on shared variance from the four wheezing-focused ISAAC-WM
items. Our findings suggest that this latent variable approach results in stronger associations
with established measures of wheezing illness severity than models using discrete severity variables based on the ISAAC-WM. Thus, for studies using the ISAAC-WM, the proposed latent
variable approach may result in stronger tests of etiological theory than models using discrete
severity variables.
It is important to note that the proposed SEM-based latent variable approach is intended
for use in explanatory research models, where the goal is to test specific etiological hypotheses
and theories. Latent variables do not yield unique scores for individual respondents [65].
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Consequently, our proposed SEM-based latent variable model of wheezing severity could not
be used in clinical practice to aid in diagnostic decisions or to make patient-specific predictions about risk for future adverse outcomes [65]. There are, however, a number of existing
questionnaires measuring wheezing severity that were designed and validated for these purposes [18]. However, for researchers testing specific etiological models of wheezing illness
development and/or outcomes with the ISAAC-WM, this approach could lead to stronger
tests of theory. We provided programming code for both lavaan (open-source) and Mplus
(proprietary) in online appendices to facilitate implementation in datasets utilizing the
ISAAC-WM.
Despite its widespread use, this was the first study, to our knowledge, to test a model of
wheezing illness severity using the ISAAC-WM. Our model was founded in the hypothesis
that wheezing severity can be conceptualized as a continuous unidimensional latent variable
and that the categorical ISAAC-WM items are surrogates, capturing measurable consequences
of this unobserved variable. In each cohort, the χ2GOF test, which is highly sensitive to model
misspecifications with large sample sizes [66,67], found no significant evidence of discrepancies between the covariance matrixes implied by our proposed model of wheezing severity and
the observed covariance matrixes.
This was also the first study to explicitly evaluate whether a model of pediatric wheezing
severity was consistent over time (longitudinal invariance) and across child sexes. Our Cohort
1 analyses suggested that the factor structure (i.e., the relationship between the latent factor
and its measured indicators) was stable over the first two years of life, allowing for meaningful
evaluation of change in pediatric wheezing severity. Although males and females differed in
their mean levels of wheezing severity, there was no evidence that the latent factor structure
was inconsistent across child sexes. This means that a single model of wheezing severity in
early childhood for girls and boys may be sufficient as long as analyses account for mean differences across sexes.
Finally, we demonstrated the benefits of using a continuous latent factor model within a
structural equation modeling framework compared to a discrete wheezing severity variable in
terms of its power to detect associations with future clinical outcomes. Going from the lowest
to highest levels of the latent factor was associated with a greater increase in the estimated
probability of future wheezing morbidity outcomes compared to going from the lowest to
highest levels of a discrete severity variable. Thus, the latent factor approach may yield more
powerful tests of etiological associations than categorical severity variables.
While there are a number of strengths of this study, including evaluation of the latent variable approach in three independent datasets, there are several limitations which should be considered. First, we relied exclusively on parent report for the measurement of both wheezing
symptoms and validity outcomes; though the ISAAC-WM was designed and validated for this
purpose. Second, we tested our factor model using just four ordinal indicators. More precise
measurements of the indicators (e.g., exact counts of wheezing episodes) should result in better
severity estimation. Greater precision might also be achieved by combining the ISAAC-WM
items with other indicators of wheezing severity, assuming that they are theoretically and
empirically commensurate with the proposed model. Third, our models were unidimensional
and only captured variability in wheezing symptoms. Prior studies suggest that asthma is a
multidimensional construct [16–18], with wheezing severity represented in one of the dimensions. Future studies should explore whether the proposed latent wheezing severity model can
be combined with other symptom dimensions to provide a more comprehensive representation of asthma severity [68,69]. Fourth, the latent factor model does not discriminate as well
among children who are low on the severity spectrum compared to those with moderate to
severe symptoms. Adding indicators that better distinguish between children with mild

PLOS ONE | https://doi.org/10.1371/journal.pone.0194739 April 17, 2018

17 / 22

A latent variable model of pediatric wheezing severity

symptoms would be desirable in future studies. Lastly, it is important to note that SEM generally requires large samples and may not be feasible in smaller studies [70].

Conclusions
In conclusion, the proposed latent variable model of pediatric wheezing illness estimates
wheezing severity as a continuous construct, is consistent with data from three independent
cohorts, and is prospectively associated with asthma morbidity. This modeling approach can
be applied in cohorts with ISAAC-WM data with a sufficient sample size by adapting the provided code. Using a latent severity approach provides more powerful testing of etiological
hypotheses.
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sample asymptotic variance-covariance matrixes (the “gamma” matrix in lavaan), and sample
sizes (n) associated with each model. As all models were covariance-structure models, these
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